
Medpace Holdings (MEDP) Stock Forecast & Price Target
Medpace Holdings (MEDP) Analyst Ratings
Bulls say
Medpace Holdings is a global contract research organization (CRO) that focuses on providing full-service drug-development and clinical trial services to biotechnology, pharmaceutical, and medical device firms. The company has a diversified portfolio of services, including bioanalytical laboratory and imaging capabilities, and a strong presence in key international markets. The recent bookings inflection and normalization of cancellations, in addition to a strong pre-backlog pipeline, support a positive outlook for the company's continued gross bookings ramp into 2027. However, potential risks in the CRO space, such as changes in government regulations and macroeconomic weakness, should be closely monitored. Overall, with a strong underlying fundamentals and a potential for future growth, Medpace is a strong investment opportunity.
Bears say
Medpace Holdings is a full-service contract research organization that provides clinical trial services to biotech, pharmaceutical, and medical device companies. However, the company's recent improvement in net bookings is primarily due to lower cancellations rather than gross bookings growth, which may suggest a structural buffer against future cancellation spikes. Additionally, Medpace's high leverage to the biopharma industry and strong momentum in CRO utilization may be at risk due to government funding delays and potential challenges in sourcing clinical trial talent or materials. The company's focus on ethical conduct and diverse leadership team may be positives, but the concentration of revenue from a few large metabolic programs may present a risk to future revenue.
This aggregate rating is based on analysts' research of Medpace Holdings and is not a guaranteed prediction by Public.com or investment advice.
Medpace Holdings (MEDP) Analyst Forecast & Price Prediction
Start investing in Medpace Holdings (MEDP)
Order type
Buy in
Order amount
Est. shares
0 shares